title: Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias.
abstract: Infant acute lymphoblastic leukaemia (ALL) represents a rare but unique subset with poor prognosis. We analysed mixed-lineage leukaemia (MLL) gene rearrangements and the sequences of complete and incomplete immunoglobulin heavy chain gene rearrangements (IGH) in 14 infants (age < or = 12 months at diagnosis) enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. The dynamics of the leukaemic clone were followed during the course of the disease by quantitative real-time polymerase chain reaction of IGH rearrangements. Sixteen sequences were obtained from 13 (93%) of these infants. There was marked over usage of the V(H)6.1 gene segment (64%) in infants compared with older children with ALL (8%), (P < 0.001) and overusage of D(H)6 (P = 0.004) and J(H)1 (P = 0.004). Poor outcome was associated with MLL gene rearrangements rather than any specific V(H)D(H)J(H) gene usage patterns. Levels of minimal residual disease (MRD) at the end of induction appeared to be high in infants with ALL compared with older children, and although the number of infant cases studied was small, there were no differences in MRD levels after induction therapy in infant ALL with or without MLL gene rearrangements (P = 0.41) and quantitative MRD assessment at the early time points may not be predictive of outcome. Novel treatment strategies are required to improve the outcome in this poor prognosis subset of children with ALL.
authors.affiliation: Department of Medical Biosciences, Pathology, Umea University, Umea, Sweden.
authors.forename: Aihong
authors.initials: A
authors.lastname: Li
authors.forename: Meredith A
authors.initials: MA
authors.lastname: Goldwasser
authors.forename: Jianbiao
authors.initials: J
authors.lastname: Zhou
authors.forename: Scott A
authors.initials: SA
authors.lastname: Armstrong
authors.forename: Hongjun
authors.initials: H
authors.lastname: Wang
authors.forename: Virginia
authors.initials: V
authors.lastname: Dalton
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Fletcher
authors.forename: Stephen E
authors.initials: SE
authors.lastname: Sallan
authors.forename: Lewis B
authors.initials: LB
authors.lastname: Silverman
authors.forename: John G
authors.initials: JG
authors.lastname: Gribben
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D003582:Cytogenetics; D015870:Gene Expression; D015322:Gene Rearrangement, B-Lymphocyte; D005803:Genes, Immunoglobulin; D006801:Humans; D007223:Infant; D015448:Leukemia, B-Cell / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D018365:Neoplasm, Residual / Q000235:genetics; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D011446:Prospective Studies; D012074:Remission Induction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents